Cancer-focused Abdera Therapeutics collects $142m for Series A, B deals

Versant Ventures and Amplitude Ventures led the Series A round, while venBio Partners led the Series B round.

To view this content, you need to sign in.

You should only be asked to sign in once. Not the case? Click here

Register now to access this content and more for free.

Share this